GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Protagonist Therapeutics
Protagonist Therapeutics is a biotech company developing peptide drugs. Its stock price is highly volatile and driven by news of clinical trials. The chart is a classic biotech story of binary events, where the success or failure of a trial determines everything.
Share prices of companies in the market segment - Pharma immune
Protagonist Therapeutics is a biotechnology company developing peptide drugs. We classify it as a Pharma-Immune company, and the chart below reflects the overall dynamics of this market segment.
Broad Market Index - GURU.Markets
Protagonist Therapeutics is a biopharmaceutical company developing peptide drugs for the treatment of hematological and immune diseases. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how Protagonist shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
PTGX - Daily change in the company's share price Protagonist Therapeutics
For Protagonist Therapeutics, a biopharmaceutical company, change_co is a measure of the sector's inherent high volatility. Each daily change reflects sensitivity to clinical trial news. This metric isn't just noise, but a critical component of the models at System.GURU.Markets that assess risk in innovative medicine.
Daily change in the price of a set of shares in a market segment - Pharma immune
Protagonist Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with PTGX, which focuses on peptide drugs, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Protagonist Therapeutics is a biopharmaceutical company developing peptide drugs. The biotech sector is known for its high volatility. The chart below shows average daily fluctuations in this industry, allowing one to assess how Protagonist's performance aligns with overall trends.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Protagonist Therapeutics
Protagonist is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Annual dynamics of market capitalization of the market segment - Pharma immune
Protagonist Therapeutics, Inc. is a clinical-stage biotechnology company developing peptide therapeutics for the treatment of hematological and inflammatory diseases. Its stock price is entirely dependent on clinical trial results, reflecting the high risks and potential for breakthroughs in this field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Protagonist Therapeutics is a clinical-stage biotech whose value reflects the promise of new drugs. Its shares are extremely volatile and completely disconnected from economic cycles. The company's chart isn't about business, but about binary events: the success or failure of clinical trials.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Protagonist Therapeutics
The performance of Protagonist, a biopharmaceutical company, depends on its R&D cycle. Monthly fluctuations on the chart reflect news about the clinical trials of its peptide drugs, the success of which determines the company's entire future value, making its shares highly volatile.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Protagonist Therapeutics develops peptide drugs for the treatment of blood diseases and inflammatory processes. This innovative approach has the potential to offer new therapeutic solutions. The chart below shows the overall dynamics in the biotech sector, where investors evaluate the scientific potential and risks of clinical development.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech stocks often take on a life of their own, reacting to trial news. The chart below shows general market trends. Is Protagonist Therapeutics following this general trend, or are its R&D events creating a completely independent story?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Protagonist Therapeutics
Protagonist Therapeutics, a biotech company developing peptide drugs, exhibits high volatility. Weekly fluctuations in its stock price are a direct response to news about the progress of clinical trials, data on the efficacy and safety of its drugs, and regulatory decisions.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Biotech companies developing peptide drugs, like Protagonist, often move together, driven by shared scientific news and breakthroughs in this area of chemistry. The chart below illustrates this common sentiment within the niche. It allows one to assess how promising the market perceives Protagonist's platform compared to its competitors.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Protagonist Therapeutics is a biotech company developing peptide drugs. Its shares are steeped in the world of clinical trials. Any news of progress or failure can trigger sharp movements that ignore the overall market situation. The chart clearly demonstrates this independence.
Market capitalization of the company, segment and market as a whole
PTGX - Market capitalization of the company Protagonist Therapeutics
Protagonist Therapeutics' market capitalization chart reflects investor expectations for its peptide drugs for the treatment of blood disorders and inflammatory conditions. Its high volatility is a direct response to clinical trial data. The scale of the company's value reflects how highly the market values the potential of its innovative scientific platform.
PTGX - Share of the company's market capitalization Protagonist Therapeutics within the market segment - Pharma immune
Protagonist Therapeutics is developing next-generation peptide drugs, aiming to capture market share in rare blood disorders and inflammatory conditions. Its market capitalization reflects progress in clinical trials and the potential of its scientific platform.
Market capitalization of the market segment - Pharma immune
This chart shows the total value of the entire biotech sector specializing in the treatment of immune diseases. For Protagonist Therapeutics, which develops innovative oral peptide drugs, this line demonstrates the scale of the market. The chart's growth reflects the enormous need for new, more convenient treatments for diseases like ulcerative colitis.
Market capitalization of all companies included in a broad market index - GURU.Markets
Protagonist Therapeutics develops peptide drugs for the treatment of blood and gastrointestinal diseases. Its market capitalization reflects the hope for a new class of drugs. In terms of the overall market, this represents the share that investors are allocating to cutting-edge scientific approaches in biopharmaceuticals.
Book value capitalization of the company, segment and market as a whole
PTGX - Book value capitalization of the company Protagonist Therapeutics
Protagonist Therapeutics develops peptide drugs, and its book value is its scientific base. This includes laboratories, patents for the technology platform, and research equipment. This is the material foundation for future drugs. Has the company increased its investment in this scientific potential? The chart below shows.
PTGX - Share of the company's book capitalization Protagonist Therapeutics within the market segment - Pharma immune
Protagonist Therapeutics develops peptide drugs, and its research requires a significant resource base. This includes cutting-edge laboratories and a proprietary technology platform for discovering and optimizing new molecules. The chart shows the company's share of the physical R&D infrastructure required to create this class of drugs.
Market segment balance sheet capitalization - Pharma immune
Protagonist Therapeutics develops peptide drugs. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. Protagonist is an R&D company; its capital comes not from factories, but from a patented platform for discovering new drugs.
Book value of all companies included in the broad market index - GURU.Markets
Protagonist Therapeutics develops next-generation peptide drugs. The company's book value is derived from its advanced technology platform, laboratories, and manufacturing facilities for creating complex molecules. The chart shows the material foundation upon which innovations in the treatment of rare blood and gastrointestinal diseases are built.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Protagonist Therapeutics
Protagonist Therapeutics' balance sheet is made up of laboratories. But the market is buying its unique platform for creating peptide drugs. The chart shows the "hope factor" and faith in the technology: how many times the potential of its developments is valued higher than its current tangible assets.
Market to book capitalization ratio in a market segment - Pharma immune
Protagonist Therapeutics develops peptide drugs for the treatment of blood and intestinal diseases. Its value depends almost entirely on the success of clinical trials. This chart illustrates a typical biotech situation: enormous market expectations with a minimal asset base.
Market to book capitalization ratio for the market as a whole
Protagonist Therapeutics develops peptide drugs for the treatment of blood disorders and inflammatory processes. The company's assets include its scientific platform and development pipeline. This chart shows the overall market valuation, but how do investors value a biotech company developing a new class of drugs with potential to treat complex diseases?
Debts of the company, segment and market as a whole
PTGX - Company debts Protagonist Therapeutics
Protagonist Therapeutics, a clinical-stage biotech company, utilizes all available instruments to finance its research. Debt can be a critical source of capital, allowing it to advance promising drugs through costly trials without issuing additional equity.
Market segment debts - Pharma immune
Protagonist Therapeutics is a biotech company developing peptide drugs for the treatment of blood diseases and inflammatory conditions. Clinical trials are a long and expensive process. This chart provides an overview of how the company raises capital to fund its research and how its financial model compares to other biotech companies.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Protagonist Therapeutics
Protagonist Therapeutics is a biopharmaceutical company developing peptide drugs for the treatment of blood and intestinal diseases. This chart shows its financial position. For a company in clinical development, whose success depends on trial results, capital structure and access to financing (including debt) are critical to continued development.
Market segment debt to market segment book capitalization - Pharma immune
Developing peptide drugs like Protagonist Therapeutics is a highly specialized and knowledge-intensive field of biotechnology. This chart shows how the pharmaceutical sector as a whole funds R&D. It allows us to assess how Protagonist's funding strategy, with its unique technology platform, differs from that of companies working with more traditional molecules.
Debt to book value of all companies in the market
This chart shows the average debt level across the entire market. Protagonist, a biotech company in the R&D stage, is entirely dependent on investor capital. Comparing it to the broader market, which is rich in profitable corporations, clearly demonstrates the unique and risky nature of a financial model based on future scientific discoveries rather than current revenue.
P/E of the company, segment and market as a whole
P/E - Protagonist Therapeutics
For Protagonist Therapeutics, a biotech company developing peptide drugs, this chart illustrates investor expectations. The high valuation, typical for the industry, is based not on current profits, but on the potential of its scientific developments in treating rare blood diseases and inflammatory conditions. It's an estimate of future scientific breakthroughs.
P/E of the market segment - Pharma immune
Peptide drug development, as Protagonist Therapeutics does, is a complex area of pharmaceuticals. This chart shows the average valuation for biotech companies. It helps to understand that Protagonist is valued based on the potential of its scientific platform and clinical trial success, not current revenue.
P/E of the market as a whole
Protagonist Therapeutics is a biotech company developing a new generation of peptide drugs for the treatment of blood disorders and inflammatory bowel diseases. This chart reflects the overall risk appetite of investors in biotech. It helps us understand whether PTGX's valuation reflects faith in its scientific platform or whether it moves in line with overall sentiment and expectations in the pharmaceutical sector.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Protagonist Therapeutics
Protagonist Therapeutics is a biotech company developing peptide drugs for the treatment of blood diseases and inflammatory conditions. This chart reflects investor expectations for clinical trials and potential approval of its drugs. Its dynamics reflect the market's assessment of the scientific and commercial potential of the company's innovative platform.
%20P%2FE%20Protagonist%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Protagonist-Therapeutics&v=1772673595303 "Chart of the company's future (projected) P/E Protagonist Therapeutics")
Future (projected) P/E of the market segment - Pharma immune
Protagonist Therapeutics is a biopharmaceutical company developing peptide drugs for the treatment of blood diseases and inflammatory conditions. This chart shows how its future revenue expectations compare to the industry average. Does the market appreciate the potential of its scientific platform and the prospects for clinical trials?
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772673595333 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Protagonist Therapeutics develops peptide drugs for the treatment of blood diseases and inflammatory processes. It is a clinical-stage biotech company. Its value is determined not by current market conditions, but by investors' faith in the science and potential of its future drugs, making it independent of general forecasts.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772673595371 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Protagonist Therapeutics
Protagonist Therapeutics is a biotech company developing peptide drugs for the treatment of blood diseases and inflammatory conditions. Its financial performance is currently driven by clinical trial costs. This chart illustrates the capital burn during the development of new drugs, which could generate significant profits if successful.
Profit of companies in the market segment - Pharma immune
Protagonist Therapeutics is a biopharmaceutical company developing peptide drugs for the treatment of blood diseases and inflammatory conditions. Its technology enables the creation of targeted and easy-to-use medications. This chart illustrates the overall dynamics in the immunology sector, where innovative treatment approaches can lead to the creation of multi-billion-dollar drugs.
Overall market profit
Protagonist Therapeutics is a biotech company developing peptide drugs. Its value depends on the success of clinical trials. However, as with the entire industry, the overall investment climate is important. This climate, reflecting the health of the economy, influences investors' willingness to fund long-term research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Protagonist Therapeutics
Protagonist Therapeutics is developing next-generation peptide drugs for the treatment of blood disorders and inflammatory bowel diseases. This is an innovative approach in pharmaceuticals. This chart represents the analyst consensus forecast, which essentially estimates the likelihood of clinical trial success and the commercial potential of their developments.
%20profit%20of%20the%20company%20Protagonist%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Protagonist-Therapeutics&v=1772673595548 "Graph of future (projected) profit of the company Protagonist Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma immune
Protagonist Therapeutics develops peptide drugs for the treatment of blood disorders and inflammatory bowel diseases. The company's approach is based on the creation of targeted therapies with an improved safety profile. This chart shows profitability projections for the biotech sector, providing context for assessing the potential of Protagonist's innovative platform in modern medicine.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772673595618 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Protagonist Therapeutics is a clinical-stage biotechnology company developing peptide therapeutics. Its value is determined solely by research progress, trial results, and the potential of its scientific developments. The company's prospects are not linked to macroeconomic cycles, as reflected in this corporate earnings forecast.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772673595666 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Protagonist Therapeutics
Protagonist Therapeutics develops peptide drugs for the treatment of blood and immune disorders. This chart shows how the market perceives the potential of its scientific platform. The ratio reflects not so much current sales as expectations for the future success of its clinical programs.
P/S market segment - Pharma immune
Protagonist Therapeutics is a biotech company developing peptide therapies for the treatment of blood disorders and inflammatory bowel diseases. This chart shows the average revenue estimate in the biotech sector. It helps understand how highly investors value the potential revenue from Protagonist's innovative platform and its drug candidates.
P/S of the market as a whole
Protagonist Therapeutics is developing next-generation peptide therapies for the treatment of blood diseases and inflammatory conditions. Their scientific approach opens up new therapeutic possibilities. This chart provides a general revenue metric against which to judge how highly investors view the potential of PTGX's innovative platform and its clinical programs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Protagonist Therapeutics
Protagonist Therapeutics develops next-generation peptide drugs for the treatment of blood diseases and inflammatory conditions. This chart reflects investor expectations for future sales of its drug candidates. The company's valuation is largely dependent on successful clinical trial results and potential approval of its innovative therapies.
%20P%2FS%20Protagonist%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Protagonist-Therapeutics&v=1772673595923 "The graph of the company's future (projected) P/S Protagonist Therapeutics")
Future (projected) P/S of the market segment - Pharma immune
Protagonist Therapeutics is a biopharmaceutical company developing novel peptide-based drugs for the treatment of hematological and inflammatory diseases. This chart compares market expectations for its pipeline with those for the speculative yet innovative biotech sector.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772673595939 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Protagonist Therapeutics is a biotech company developing peptide drugs for the treatment of blood and immune disorders. This chart reflects investors' overall risk appetite. During periods when the market expects growth, investors are more inclined to invest in innovative biotech companies whose value is based on the future potential of their research.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772673595992 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Protagonist Therapeutics
Protagonist Therapeutics is a biopharmaceutical company developing next-generation peptide therapies for the treatment of blood diseases and inflammatory conditions. This chart reflects revenue, which primarily comes from strategic partnerships and licensing agreements with major pharmaceutical companies. It illustrates the company's financial support for cutting-edge scientific research.
Sales of companies in the market segment - Pharma immune
Protagonist Therapeutics is a biopharmaceutical company developing next-generation peptide therapies for the treatment of blood diseases and inflammatory conditions. Its activities are segmented by specific drug development programs. This chart depicts the financial flows associated with one of its lead candidates, demonstrating its clinical and commercial progress.
Overall market sales
Protagonist Therapeutics is a biopharmaceutical company developing peptide drugs for the treatment of blood diseases and inflammatory conditions. Its value is determined by progress in clinical trials. The company operates at the forefront of science, creating potential medical breakthroughs that can bring enormous value to patients and the healthcare system.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Protagonist Therapeutics
Protagonist Therapeutics is a biopharmaceutical company developing peptide therapies for the treatment of hematological and immune diseases. This sales forecast is based on the expected commercial success of its key drug for the treatment of a rare blood disorder. It demonstrates the market's confidence in the potential of its innovative therapeutic platform.
%20sales%20of%20the%20company%20Protagonist%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Protagonist-Therapeutics&v=1772673596276 "Schedule of future (projected) sales of the company Protagonist Therapeutics")
Future (projected) sales of companies in the market segment - Pharma immune
Protagonist Therapeutics develops peptide drugs for the treatment of blood diseases and inflammatory conditions. This chart shows revenue expectations for the biotech sector. It reflects analysts' views on the commercial potential of new drug classes and the overall investment climate in the development of innovative therapies.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772673596317 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Protagonist Therapeutics, a biopharmaceutical company developing peptide drugs, is a company whose market capitalization and funding are dependent on investor faith in its science and the overall market appetite for risk. This chart of overall sales forecasts reflects economic sentiment, which impacts capital availability for the biotech sector.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772673596412 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Protagonist Therapeutics
Protagonist Therapeutics is a biopharmaceutical company developing peptide drugs for the treatment of blood diseases and inflammatory conditions. Being in clinical development, its financials reflect high R&D expenditures. This chart shows the current ratio of R&D investment to revenue, shaping the path to future commercialization.
Market segment marginality - Pharma immune
Protagonist Therapeutics is a biotech company developing peptide drugs for the treatment of blood diseases and inflammatory conditions. Their scientific platform allows them to create drugs that can be taken orally, a significant advantage. This graph provides an idea of the potential operational effectiveness of their innovative drug discovery approach.
Market marginality as a whole
Protagonist Therapeutics is a biopharmaceutical company developing peptide drugs for the treatment of blood and intestinal diseases. Its value is based on the potential of its scientific platform. This chart shows the profitability of mature companies, while PTGX's success depends on the results of clinical trials and the future commercialization of innovative drugs.
Employees in the company, segment and market as a whole
Number of employees in the company Protagonist Therapeutics
Protagonist Therapeutics develops peptide drugs for the treatment of blood and immune disorders. This chart shows the growth of its scientific team. The increase in this intellectual capital is a direct indicator of progress in clinical programs and the expansion of its development pipeline.
Share of the company's employees Protagonist Therapeutics within the market segment - Pharma immune
Protagonist Therapeutics develops peptide drugs for the treatment of blood and gastrointestinal diseases. Biotech research is a marathon that requires a dedicated team of scientists. This metric reflects the company's extensive talent pool in this innovative field, demonstrating its investment in long-term scientific development.
Number of employees in the market segment - Pharma immune
Protagonist Therapeutics develops peptide drugs for the treatment of blood and immune disorders. This chart reflects employment in the immunology sector. The growing number of scientists and researchers in this field indicates significant progress in understanding the immune system and active investment in the development of new classes of drugs.
Number of employees in the market as a whole
Protagonist Therapeutics is a biotech company whose operations require significant investment. A strong economy with high employment rates creates favorable conditions for attracting capital for research and development. This allows the company to confidently advance its innovative drugs through clinical trials.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Protagonist Therapeutics (PTGX)
Protagonist Therapeutics is a biotech company developing peptide drugs. Its value is based on the potential of its scientific platform. The extremely high market capitalization per employee, visible in this chart, reflects investors' bet that a small team of scientists will be able to create breakthrough drugs, making intellectual capital its most valuable asset.
%20of%20the%20company%20Protagonist%20Therapeutics%20(PTGX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Protagonist-Therapeutics-PTGX&v=1772673597098 "Chart of market capitalization per employee (in thousands of dollars) of the company Protagonist Therapeutics (PTGX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Protagonist (PTGX) is a clinical-stage biotech company working on peptide drugs. Its value comes from pure R&D. This chart shows the (speculative) market value the market attributes to each elite scientist, not its current operations.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772673597120 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Protagonist Therapeutics is a biopharmaceutical company developing peptide drugs for the treatment of blood diseases and inflammatory conditions. Its value is based on its scientific platform and clinical trial results. The chart shows the market's speculative valuation of the potential generated by a small research team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772673597142 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Protagonist Therapeutics (PTGX)
Protagonist Therapeutics is a biotech company developing peptide drugs for the treatment of blood disorders and inflammatory bowel diseases. Being in clinical development, the company likely does not have stable profitability. This chart reflects the intensity of R&D. It shows how much capital is invested in each scientist to advance their innovative platform toward commercialization.
%20Chart%20Protagonist%20Therapeutics%20(PTGX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Protagonist-Therapeutics-PTGX&v=1772673597176 "Company Profit Per Employee (in thousands of dollars) Chart Protagonist Therapeutics (PTGX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Protagonist (PTGX) is a biotech company developing peptide-based drugs (pills instead of injections). This chart shows the benchmark for "Pharma-immune" (Biotech). In this R&D sector, the benchmark is likely *negative*. Companies burn billions on R&D. Profit per scientist is a distant goal.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772673597217 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Protagonist Therapeutics (PTGX) is a biopharmaceutical company developing next-generation peptide therapies for the treatment of hematological (blood) and immune diseases. This graph, showing average profit per employee, is important for biotech. It allows one to assess how much a sector where a handful of scientists can create a breakthrough drug outperforms the "average" labor efficiency.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772673597282 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Protagonist Therapeutics (PTGX)
Protagonist Therapeutics is a biotech company developing peptide drugs. Its revenue can be volatile during the clinical stage. This chart shows the potential: if one of its drugs is successful, revenue per employee could skyrocket, reflecting the high scientific value and market potential of its developments.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Protagonist-Therapeutics-PTGX&v=1772673597325 "Sales chart per company employee Protagonist Therapeutics (PTGX)")
Sales per employee in the market segment - Pharma immune
Protagonist Therapeutics is a biopharmaceutical company developing peptide drugs for the treatment of blood and immune disorders. This chart shows revenue per employee. For a company in the R&D stage, comparing this to the segment (especially if there is revenue from partnerships) helps evaluate the effectiveness of their scientific platform.
Sales per employee for the market as a whole
Protagonist Therapeutics is a biotech company developing peptide drugs for the treatment of blood disorders and inflammatory conditions. They are in the clinical stage. Revenue, if any, likely comes from partnerships (like Arrowhead). This chart shows how much value (revenue from partners) their R&D team generates, or whether it would be zero if they rely on venture capital.
Short shares by company, segment and market as a whole
Shares shorted by company Protagonist Therapeutics (PTGX)
Protagonist Therapeutics is a biotech company developing peptide drugs for the treatment of blood and immune disorders. Like any development-stage biotech, the company's future depends on success in clinical trials. This chart shows the number of investors who are skeptical about the chances of their key drugs receiving FDA approval.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Protagonist-Therapeutics-PTGX&v=1772673597436 "Short Shares Chart for the Company Protagonist Therapeutics (PTGX)")
Shares shorted by market segment - Pharma immune
Protagonist Therapeutics (PTGX) is a biopharmaceutical company developing peptide drugs for the treatment of blood and immune disorders. This chart shows the bets against the biotech sector. It reflects the high level of uncertainty and investor skepticism regarding clinical trial data and the chances of regulatory approval.
Shares shorted by the overall market
Protagonist (PTGX) is a clinical-stage biotech. This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives PTGX of access to the capital needed for expensive trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Protagonist Therapeutics (PTGX)
Protagonist Therapeutics is a clinical-stage biotech. Its shares are highly sensitive to trial news. This chart for PTGX can surge above 70 on positive R&D data. Oversold levels (<30) often reflect research setbacks or general investor risk aversion in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Protagonist-Therapeutics-PTGX&v=1772673597539 "RSI 14 indicator chart for the company's stock Protagonist Therapeutics (PTGX)")
RSI 14 Market Segment - Pharma immune
Protagonist Therapeutics (PTGX) is a biotech company developing peptide drugs for the treatment of immune and hematological diseases. The RSI_14_Seg for "Pharma immune" shows whether the entire biotech segment is overheated. The chart helps us understand whether PTGX's growth is a reaction to its trials or simply general hype in the sector.
RSI 14 for the overall market
Protagonist Therapeutics (PTGX) is a biotech company whose fate depends on this schedule. To fund expensive clinical trials, it requires a constant influx of capital. During periods of market euphoria, investors generously fund risky developments. During periods of panic, the "cash spigot" is turned off, and companies like PTGX are forced to struggle to survive.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PTGX (Protagonist Therapeutics)
Protagonist Therapeutics is a biotech company developing next-generation peptide drugs, many of which can be taken orally (as tablets) rather than by injection. This chart shows the average analyst forecast. Their target prices are based on the clinical progress of their drug candidates for the treatment of immune and hematological diseases.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PTGX-Protagonist-Therapeutics&v=1772673597670 "A chart showing analyst consensus forecasts for the expected stock price. PTGX (Protagonist Therapeutics)")
The difference between the consensus estimate and the actual stock price PTGX (Protagonist Therapeutics)
Protagonist Therapeutics (PTGX) is a biotech company developing a new class of peptide drugs for the treatment of rare blood diseases and inflammatory conditions. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high potential analysts see in their lead drug candidates.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PTGX-Protagonist-Therapeutics&v=1772673597705 "A chart showing the difference between the consensus forecast and the actual stock price. PTGX (Protagonist Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Protagonist Therapeutics is a biotech company developing a new class of drugs—peptides. Its R&D platform targets the treatment of immune diseases and blood cancers. This chart shows analysts' overall expectations for the immune pharma sector, reflecting whether experts believe this new technology will be successful.
Analysts' consensus forecast for the overall market share price
Protagonist Therapeutics is a biotech company developing peptide drugs for the treatment of blood disorders and inflammatory bowel diseases. This chart shows the overall risk appetite. For Protagonist, as a clinical-stage company, overall market optimism is important for raising the capital needed to complete costly clinical trials and enter the market.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Protagonist Therapeutics
Protagonist Therapeutics is a biotech company developing peptide drugs (small proteins). Their lead candidate (Rusfertide) targets the rare blood disorder polycythemia vera. This schedule is an assessment of their R&D platform. It is entirely dependent on clinical data, FDA approval, and the market potential of their lead drug candidates.
AKIMA Market Segment Index - Pharma immune
Protagonist is a biotech focused on peptide drugs; the company develops targeted therapies for immune diseases (ulcers) and rare blood disorders. This summary metric evaluates R&D. The graph shows the average value for the segment. This benchmark: how does Protagonist's niche (peptide) R&D platform differentiate it from the average pharma company?
The AKIM Index for the overall market
Protagonist is a biotech company focused on developing peptide drugs for the treatment of blood diseases and inflammation. It's a high-risk scientific bet. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this speculative story, driven by trial news, compares to overall economic trends.
